Back

Atrial fibrillation is associated with worse outcome in patients with wild-type transthyretin amyloid cardiomyopathy

18 May 2025 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: From epidemiology to outcomes Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Assistant Professor Gregor Zemljic

University Medical Centre Ljubljana, Ljubljana (Slovenia)

5 More presentations in this session

Presentation thumbnail
Obesity and inactivity cluster is the strongest predictor of incident heart failure in a population-based study
Mr B. Van Essen (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
comparing diagnostic modalities and time to diagnosis in transthyretin amyloidosis: insights from a multi-ethnic asian registry
Doctor V. Putri (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure
Mr D. Ceelen (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Diabetes, cancer and heart failure: a network of reciprocal epidemiological interactions with prognostic implications
Doctor A. Iaconelli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Cardiopulmonary resuscitation preferences among elderly patients admitted for heart failure
Doctor P. Salamanca Bautista (Seville, ES)
Abstract Slides Video

Access the full session

Session thumbnail
From epidemiology to outcomes

The Event

Event poster

Heart Failure 2025

18 May 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Trends in prevalence and clinical outcomes of patients with atrial fibrillation and cardiac amyloidosis- from a nationwide registry
thumbnail
Congress Presentation
Tafamidis reduces the burden of atrial fibrillation in patients with wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Impact of rhythm control in wild-type transthyretin cardiac amyloidosis and atrial fibrillation: a retrospective analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources